

#### 4.9.1: Published policies (26) (1 April 2025 –16 February 2026)

Policy Number	Title	Commissioning Team	Publication date
SS238	WELSH ARTIFICIAL EYE SERVICE (WAES) (ALL AGES), SERVICE SPECIFICATION <a href="#">[UPDATE]</a>	NEUROSCIENCES AND LONG-TERM CONDITIONS	6 February 2026
PPS256	IMLIFIDASE FOR DESENSITISATION TREATMENT BEFORE KIDNEY TRANSPLANT IN PEOPLE WITH CHRONIC KIDNEY DISEASE <a href="#">[NEW]</a>	WELSH KIDNEY NETWORK	6 February 2026
PPS301	BELUMOSUDIL FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE IN PEOPLE AGED 12-17 YEARS AFTER 2 OR MORE SYSTEMIC TREATMENTS, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	CANCER AND BLOOD	6 February 2026
CP325	HOME THERAPIES SERVICE FOR ADULTS REQUIRING DIALYSIS, COMMISSIONING POLICY <a href="#">[NEW]</a>	WELSH KIDNEY NETWORK	6 February 2026
SS325	HOME THERAPIES SERVICE FOR ADULTS REQUIRING DIALYSIS, SERVICE SPECIFICATION <a href="#">[NEW]</a>	WELSH KIDNEY NETWORK	6 February 2026
CP49	WAR VETERANS – ENHANCED PROSTHETIC PROVISION, COMMISSIONING POLICY <a href="#">[UPDATE]</a>	NEUROSCIENCES AND LONG-TERM CONDITIONS	5 February 2026
PPS177	BUROSUMAB FOR X-LINKED HYPOPHOSPHATAEMIA IN CHILDREN AND YOUNG PEOPLE, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	NEUROSCIENCES AND LONG-TERM CONDITIONS	5 February 2026
SS149	SOFT TISSUE SARCOMA, SERVICE SPECIFICATION <a href="#">[UPDATE]</a>	CANCER AND BLOOD	30 November 2025
PPS315	ANHYDROUS SODIUM THIOSULFATE (PEDMARQSI) FOR PREVENTING OTOTOXICITY CAUSED BY CISPLATIN CHEMOTHERAPY IN PEOPLE AGED 1 MONTH TO 17 YEARS WITH LOCALISED SOLID TUMOURS, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	WOMEN AND CHILDREN	30 November 2025
PPS317	BELIMUMAB FOR TREATING ACTIVE AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHERMATOSUS IN PEOPLE	WOMEN AND CHILDREN	30 November 2025

Policy Number	Title	Commissioning Team	Publication date
	AGED 5-17 YEARS, POLICY POSITION STATEMENT <a href="#">[NEW]</a>		
CP50	POSITRON EMISSION TOMOGRAPHY (PET), COMMISSIONING POLICY <a href="#">[UPDATE]</a>	CANCER AND BLOOD	12 September 2025
PPS167	EMICIZUMAB AS PROPHYLAXIS IN PEOPLE WITH CONGENITAL HAEMOPHILIA A WITH FACTOR VIII INHIBITORS (ALL AGES), POLICY POSITION STATEMENT <a href="#">[UPDATE]</a>	CANCER AND BLOOD	12 September 2025
CP221	RECREATIONAL AND SPORT PROSTHETICS FOR PEOPLE UNDER THE AGE OF 25 YEARS, COMMISSIONING POLICY <a href="#">[UPDATE]</a>	NEUROSCIENCES AND LONG-TERM CONDITIONS	12 September 2025
PPS191	NUSINERSEN FOR TREATING CHILDREN UP TO 17 YEARS WITH SPINAL MUSCULAR ATROPHY, POLICY POSITION STATEMENT <a href="#">[UPDATE]</a>	WOMEN AND CHILDREN	5 September 2025
PPS217	VOLANESORSEN FOR TREATING FAMILIAL CHYLOMICRONAEMIA SYNDROME, POLICY POSITION STATEMENT <a href="#">[UPDATE]</a>	WOMEN AND CHILDREN	5 September 2025
CP55	DRUG TREATMENT FOR LYSOSOMAL STORAGE DISORDERS (ALL AGES), COMMISSIONING POLICY <a href="#">[UPDATE]</a>	WOMAN AND CHILDREN	8 August 2025
SS169	PAEDIATRIC NEPHROLOGY, SERVICE SPECIFICATION <a href="#">[UPDATE]</a>	WOMEN AND CHILDREN	8 August 2025
PPS308	EVINACUMAB FOR TREATING HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN PEOPLE 12 YEARS AND OVER, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	WOMEN AND CHILDREN	8 August 2025
SS205	CARDIAC SURGERY, SERVICE SPECIFICATION <a href="#">[NEW]</a>	CARDIAC	8 August 2025
SS183	RADIOFREQUENCY ABLATION (RFA) IN THE MANAGEMENT OF BARRETT'S OESOPHAGUS IN ADULTS ,SERVICE SPECIFICATION <a href="#">[UPDATE]</a>	CANCER AND BLOOD	18 June 2025

<b>Policy Number</b>	<b>Title</b>	<b>Commissioning Team</b>	<b>Publication date</b>
CP183	RADIOFREQUENCY ABLATION (RFA) IN THE MANAGEMENT OF BARRETT'S OESOPHAGUS IN ADULTS, COMMISSIONING POLICY <a href="#">[UPDATE]</a>	CANCER AND BLOOD	18 June 2025
CP297	VASCULAR ACCESS, COMMISSIONING POLICY <a href="#">[NEW]</a> <a href="#">[NEW]</a>	WELSH KIDNEY NETWORK	18 June 2025
SS297	VASCULAR ACCESS, SERVICE SPECIFICATION <a href="#">[NEW]</a>	WELSH KIDNEY NETWORK	18 June 2025
PPS203	DRUG TREATMENTS FOR SEIZURES ASSOCIATED WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME IN PEOPLE AGED 2 YEARS AND OLDER, POLICY POSITION STATEMENT <a href="#">[UPDATE]</a>	WOMEN AND CHILDREN	17 April 2025
PPS306	TAFAMIDIS FOR TREATING TRANSYTHRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	CARDIAC	11 April 2025
PPS298	SETMELANOTIDE FOR TREATING OBESITY AND HYPERPHAGIA IN BARDET-BIEDL SYNDROME, POLICY POSITION STATEMENT <a href="#">[NEW]</a>	WOMEN AND CHILDREN	11 April 2025